Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer
Status:
Terminated
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. To examine the effect of celecoxib treatment on histological response, markers of
proliferation (Ki-67), and apoptosis. Secondary endpoints include time to second primary
or recurrence and survival.
2. To examine the toxicity associated with celecoxib administration in patients with
previously treated Head and Neck Head and neck squamous cell carcinomas (HNSCC)or
Non-small-cell lung carcinoma (NSCLC).